ArticleJCO global oncology2020
Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets.
Article in JCO global oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020.Frontiers in oncology · 2021Pooled it
- COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.Clinical pharmacology and therapeutics · 2021Trial
- A Single-Center, Retrospective, Real-World, Observational Clinical Study to Evaluate the Safety and Efficacy of Abiraterone (Abiratred) in Patients with Metastatic Prostate Cancer.South Asian journal of cancer · 2025Article
- Article
- Treatment approaches for prostate cancer in sub-Saharan Africa.Translational cancer research · 2024Review
- Low-dose abiraterone plus Olaparib as a late-line treatment for mCRPC patients without BRCA1/2 mutations: a multicenter retrospective pilot study.Scientific reports · 2024Article
- Optimising oncology drug expenditure in Ireland.Irish journal of medical science · 2024Review
- Comparative analysis of real-world data of frequent treatment sequences in metastatic prostate cancer.Current urology · 2024Article
- Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India.Applied health economics and health policy · 2024Article
- The Lancet Commission on prostate cancer: planning for the surge in cases.Lancet (London, England) · 2024Review
- Prostate cancer management in Southeast Asian countries: a survey of clinical practice patterns.Therapeutic advances in medical oncology · 2024Article
- Outcomes and toxicity of oral Fosfestrol in metastatic castration-resistant prostate cancer-a real-world experience.Ecancermedicalscience · 2023Article
- Priorities for cancer research in low- and middle-income countries: a global perspective.Nature medicine · 2022Review
- Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings.NPJ breast cancer · 2022Article
- Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer.Prostate international · 2022Article
- Clinical research in oncology: in memory of Professor Gordon McVie.Ecancermedicalscience · 2022Article
- Epidemiology and genomics of prostate cancer in Asian men.Nature reviews. Urology · 2021Review
- Low-Dose Abiraterone, a Rare European Commodity.JCO global oncology · 2020Article
- Potential Cost Savings With Low-Dose Abiraterone in the United States.JCO global oncology · 2020Article
- Strategies for Improving Access to Effective Prostate Cancer Medications (Abiraterone and Enzalutamide) in Low- and Middle-Income Countries (LMICs): A Survey Among Nigerian Health Professionals.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIt is projected that approximately 50,000 new cases of prostate cancer will be diagnosed in 2020 in India. Survival has improved because of the development of effective drugs such as abiraterone acetate, but universal accessibility to treatment is not always possible because of cost constraints in lower- and middle-income countries. Recently, the National Comprehensive Cancer Network (NCCN) has included low-dose abiraterone (250 mg/day) with food as an alternative treatment option to full-dose abiraterone (1,000 mg/day) fasting.
methodsThe Science and Cost Cancer Consortium conducted a survey to evaluate the use of abiraterone in India and the opinions of medical oncologists about using low-dose treatment. Modeling was used to estimate potential financial benefits to individual patients and to estimate overall costs of health care in India if low-dose abiraterone is prescribed.
resultsOf 251 Indian medical oncologists who were invited to participate in the survey, 125 provided their e-mail address and received the survey; 118 responded (47% of the total). Of these, 25% were not aware of the recent NCCN recommendation, 55% were already prescribing low-dose abiraterone when resources were limited, 7% had already changed their practice, and 29% agreed to switch to a universal practice of using low-dose abiraterone with food; 9% of practitioners would not use low-dose abiraterone. Estimated mean per patient savings was US$3,640, with annual savings of US$182 million in India.
conclusionUse of lower-dose abiraterone would increase access to treatment in India and globally and lead to large cost savings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.